In last two decades, a large number of papers have been published describing novel GCPII inhibitors acting as neuroprotective drugs 28, 44 and GCPII inhibitor‐based tools for imaging and/or treating prostate cancer 19, 20, 45, 46, 47. The gene discussed is FOLH1; the disease is prostate cancer.